Panacea Life Sciences Holdings, Inc. Selling and Marketing Expense
Panacea Life Sciences Holdings, Inc. (PLSH) reported Selling and Marketing Expense of $26.10 thousand for the 3-month period ending 2021-03-31, per its 10-Q/A filed 2021-05-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2021-05-27
- Panacea Life Sciences Holdings, Inc. selling and marketing expense for the quarter ending 2021-03-31 was $26.10K, a 90.71% decline year-over-year.
- Panacea Life Sciences Holdings, Inc. selling and marketing expense for the quarter ending 2020-12-31 was $133.51K, a 61.04% decline year-over-year.
- Panacea Life Sciences Holdings, Inc. selling and marketing expense for the quarter ending 2020-09-30 was $92.12K, a 75.57% decline year-over-year.
- Panacea Life Sciences Holdings, Inc. selling and marketing expense for the quarter ending 2020-06-30 was $132.11K, a 64.97% decline year-over-year.
- Panacea Life Sciences Holdings, Inc. selling and marketing expense for fiscal 2020 was $638.63K, a 32.65% decline from fiscal 2019.
- Panacea Life Sciences Holdings, Inc. selling and marketing expense for fiscal 2019 was $948.30K, a 5157.80% increase from fiscal 2018.
- Panacea Life Sciences Holdings, Inc. selling and marketing expense for fiscal 2018 was $18.04K.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $26.10K 10-Q/A · filed 2021-05-27 | $159.60K derived: sum of 2 quarters · filed 2021-05-27 | $251.73K derived: sum of 3 quarters · filed 2021-05-27 | $383.84K derived: sum of 4 quarters · filed 2021-05-27 | |
| 2020-12-31 | $133.51K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-23 | $225.63K derived: sum of 2 quarters · filed 2021-04-23 | $357.74K derived: sum of 3 quarters · filed 2021-04-23 | $638.63K 10-K/A · filed 2021-04-23 | |
| 2020-09-30 | $92.12K 10-Q · filed 2020-11-18 | $224.23K derived: sum of 2 quarters · filed 2020-11-18 | $505.12K 10-Q · filed 2020-11-18 | $847.82K derived: sum of 4 quarters · filed 2021-05-27 | |
| 2020-06-30 | $132.11K 10-Q · filed 2020-08-19 | $413.00K 10-Q · filed 2020-08-19 | $755.70K derived: sum of 3 quarters · filed 2021-05-27 | $1.13M derived: sum of 4 quarters · filed 2021-05-27 | |
| 2020-03-31 | $280.89K 10-Q/A · filed 2021-05-27 | $623.59K derived: sum of 2 quarters · filed 2021-05-27 | $1.00M derived: sum of 3 quarters · filed 2021-05-27 | $1.38M derived: sum of 4 quarters · filed 2021-05-27 | |
| 2019-12-31 | $342.70K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-23 | $719.82K derived: sum of 2 quarters · filed 2021-04-23 | $1.10M derived: sum of 3 quarters · filed 2021-04-23 | $948.30K 10-K/A · filed 2021-04-23 | |
| 2019-09-30 | $377.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-18 | $754.23K derived: sum of 2 quarters · filed 2020-11-18 | $605.60K 10-Q · filed 2020-11-18 | ||
| 2019-06-30 | $377.12K 10-Q · filed 2020-11-18 | $176.60K 10-Q · filed 2020-08-19 | $228.48K 10-Q · filed 2020-08-19 | ||
| 2019-03-31 | $51.88K 10-Q · filed 2020-06-29 | ||||
| 2018-12-31 | $18.04K 10-K · filed 2020-05-22 |